Diagnostic Value of IgA antiVCA Epstein-Barr Antibody in Nasophryngeal Carcinoma

2015 ◽  
Vol 21 (2) ◽  
pp. 162
Author(s):  
Betty Agustina Tambunan ◽  
Aryati . ◽  
Windu Nafika
Keyword(s):  
Early Diagnosis ◽  
Epstein Barr Virus ◽  
Early Stage ◽  
Positive Likelihood Ratio ◽  
Diagnostic Value ◽  
Elisa Method ◽  
Serological Method ◽  
Positive Predict Value ◽  
Barr Virus ◽  
Epstein Barr

Early diagnosis of nasopharyngeal carcinoma (NPC) is difficult, so most patients arrived already in an advanced stage. The biopsyas the gold standard for the diagnosis of NPC at an early stage also have limitations. Epstein-Barr virus as the cause of NPC is pavingthe way for early diagnosis was through serological method. The purpose of this study is to know the diagnostic value of IgA antiviralcapsid antigen (VCA) Epstein-Barr antibody for NPC by analyzing it. The samples were NPC patients and others whome have head-neckmalignancies arrived in the Oncology Outpatient Clinic, Dr. Soetomo Hospital. Their sera were examined for IgA antiVCA Epstein-Barrantibody using ELISA method and then analyzed for its diagnostic value using the 2x2 table with a 95% confidence interval. IgA antiVCAcutoff was determined by ROC. The results show that the diagnostic value of IgA antiVCA Epstein-Barr antibody have the sensitivityand specificity around 93.3% and 93.8%, respectively. Positive predict value was 96.6%% and the negative one was 88.2%, while thediagnostic efficiency was 93.5%. The positive likelihood ratio was 14.9 times and the negative was only 0.07. The cut off value of IgAantiVCA according ROC was 13.45 U/mL with AUC 97.9%. Based on this study, can be concluded that IgA antiVCA Epstein-Barr antibodyshowed an excellent validity in supporting the diagnosis of NPC. However, the researchers needed further research to know the obtainableearly stage of NPC.

scholarly journals NILAI DIAGNOSTIK IgA ANTIVCA ANTIBODI EPSTEIN-BARR DI KARSINOMA NASOFARING

2018 ◽  
Vol 21 (2) ◽  
pp. 162
Author(s):  
Betty Agustina Tambunan ◽  
Aryati Aryati ◽  
Windu Nafika
Keyword(s):  
Early Diagnosis ◽  
Epstein Barr Virus ◽  
Early Stage ◽  
Positive Likelihood Ratio ◽  
Diagnostic Value ◽  
Elisa Method ◽  
Serological Method ◽  
Positive Predict Value ◽  
Barr Virus ◽  
Epstein Barr

Early diagnosis of nasopharyngeal carcinoma (NPC) is difficult, so most patients arrived already in an advanced stage. The biopsyas the gold standard for the diagnosis of NPC at an early stage also have limitations. Epstein-Barr virus as the cause of NPC is pavingthe way for early diagnosis was through serological method. The purpose of this study is to know the diagnostic value of IgA antiviralcapsid antigen (VCA) Epstein-Barr antibody for NPC by analyzing it. The samples were NPC patients and others whome have head-neckmalignancies arrived in the Oncology Outpatient Clinic, Dr. Soetomo Hospital. Their sera were examined for IgA antiVCA Epstein-Barrantibody using ELISA method and then analyzed for its diagnostic value using the 2x2 table with a 95% confidence interval. IgA antiVCAcutoff was determined by ROC. The results show that the diagnostic value of IgA antiVCA Epstein-Barr antibody have the sensitivityand specificity around 93.3% and 93.8%, respectively. Positive predict value was 96.6%% and the negative one was 88.2%, while thediagnostic efficiency was 93.5%. The positive likelihood ratio was 14.9 times and the negative was only 0.07. The cut off value of IgAantiVCA according ROC was 13.45 U/mL with AUC 97.9%. Based on this study, can be concluded that IgA antiVCA Epstein-Barr antibodyshowed an excellent validity in supporting the diagnosis of NPC. However, the researchers needed further research to know the obtainableearly stage of NPC.

scholarly journals Clinical value of a plasma Epstein–Barr virus DNA assay in the diagnosis of recurrent or metastatic nasopharyngeal carcinoma: a meta-analysis

2019 ◽  
Vol 39 (9) ◽  
Author(s):  
Haiqin Peng ◽  
Zhanzhan Li ◽  
Yujiao Long ◽  
Jiahui Li ◽  
Zhiyuan Liu ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Likelihood Ratio ◽  
Epstein Barr Virus ◽  
Meta Analysis ◽  
Positive Likelihood Ratio ◽  
Diagnostic Value ◽  
Barr Virus ◽  
Ebv Dna ◽  
Epstein Barr ◽  
Sensitivity Specificity

Abstract Background: To evaluate the diagnostic value of Epstein–Barr virus (EBV) DNA in nasopharyngeal carcinoma (NPC) patients with locoregional or distant recurrence. Methods: Articles related to the diagnosis of recurrent or metastatic NPC by the detection of EBV DNA in plasma or serum were retrieved from different databases. Sensitivity, specificity, summary receiver operating characteristic (SROC) curves, and likelihood ratios were pooled to assess the diagnostic value of individual diagnostic tests. Results: This meta-analysis pooled 25 eligible studies including 2496 patients with NPC. The sensitivity, specificity, positive likelihood ratio (+LR), and negative likelihood ratio (−LR) of EBV DNA in the diagnosis of NPC were 0.858 (95% confidence interval (CI): 0.801–0.901), 0.890 (95% CI: 0.866–0.909), 7.782 (95% CI: 6.423–9.429) and 0.159 (95% CI: 0.112–0.226), respectively. The diagnostic odds ratio (DOR) was 48.865 (95% CI: 31.903–74.845). The SROC for EBV DNA detection was 0.93 (95% CI: 0.90–0.95). Conclusion: The detection of EBV DNA for the diagnosis of recurrent or metastatic NPC has good sensitivity and specificity and might be helpful in monitoring recurrent or metastatic NPC.

scholarly journals Plasma Macrophage Inhibitory Cytokine-1 as a Complement of Epstein-Barr Virus Related Markers in Identifying Nasopharyngeal Carcinoma

2020 ◽  
Vol 19 ◽  
pp. 153303382095699
Author(s):  
Shan Xing ◽  
Huilan Li ◽  
Yingqi Pi ◽  
Tao Zeng ◽  
Qi Huang ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Copy Number ◽  
Epstein Barr Virus ◽  
Normal Subjects ◽  
Diagnostic Value ◽  
Healthy Controls ◽  
Barr Virus ◽  
Healthy Donors ◽  
Ebv Dna ◽  
Epstein Barr

Background: We evaluated the diagnostic value of plasma Macrophage inhibitory cytokine-1 (MIC-1) in distinguishing patients with nasopharyngeal carcinoma (NPC) and explored its complementary role with widely used Epstein-Barr virus (EBV) related markers, EBV capsid antigen-specific IgA (VCA-IgA) and EBV copy number. Methods: ELISA was used to analyze the plasma MIC-1 levels in 190 NPC patients, 72 VCA-IgA-positive healthy donors (VP), and 219 normal subjects with negative VCA-IgA (VN). 10 pairs of plasma samples before and after radiotherapy were also included. Results: The plasma MIC-1 levels were significantly higher in NPC patients (Median: 678.39 ng/mL) than those in VN and VP (310.29 and 294.59, p < 0.001). Receiver operating characteristic (ROC) curves of the MIC-1 concentrations revealed that the area under the ROC curve (AUC) was 0.790 (95% confidence interval [CI]: 0.748-0.832), with a sensitivity of 63.7%, and a specificity of 85.9% respectively, for distinguishing NPC patients from the healthy donors. Similarly, between NPC and VP, ROC was 0.796 (0.738-0.853) with sensitivity of 63.7%, and specificity of 88.9%. In addition, between NPC and VN, ROC was 0.788(0.744-0.832) with sensitivity of 63.7%, and specificity of 84.9%. Further, we found that MIC-1 could complement VCA-IgA and EBV DNA markers, with a negative rate of 88.9% in VCA-IgA-positive healthy controls, and a positive rate of 59.0% in EBV DNA negative NPC patients, respectively. Also, the MIC-1 plasma concentration dropped significantly after radiotherapy ( p = 0.027). Conclusions: MIC-1 can complement VCA-IgA titers and EBV DNA copy number tests in NPC detection, improve identification of EBV DNA-negative NPC patients, and distinguish NPC from VCA -IgA positive healthy controls.

scholarly journals Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy

Blood ◽  
2012 ◽  
Vol 120 (10) ◽  
pp. 2003-2010 ◽  
Author(s):  
Zhao-Yang Wang ◽  
Qing-Feng Liu ◽  
Hua Wang ◽  
Jing Jin ◽  
Wei-Hu Wang ◽  
...  
Keyword(s):  
Epstein Barr Virus ◽  
Cell Lymphoma ◽  
Early Stage ◽  
Stage I ◽  
Nasal Type ◽  
Barr Virus ◽  
Tumor Load ◽  
Primary Radiotherapy ◽  
Ebv Dna ◽  
Epstein Barr

Abstract The clinical value of plasma Epstein-Barr virus (EBV) DNA has not been evaluated in patients with early-stage extranodal nasal-type NK/T-cell lymphoma (NKTCL) receiving primary radiotherapy. Fifty-eight patients with stage I disease and 11 with stage II disease were recruited. High pretreatment EBV-DNA concentrations were associated with B-symptoms, elevated lactate dehydrogenase levels, and a high International Prognostic Index score. EBV-DNA levels significantly decreased after treatment. The 3-year overall survival (OS) rate was 82.6% for all patients. Stage I or II patients with a pretreatment EBV-DNA level of ≤ 500 copies/mL had 3-year OS and progression-free survival (PFS) rates of 97.1% and 79.0%, respectively, compared with 66.3% (P = .002) and 52.2% (P = .045) in patients with EBV-DNA levels of > 500 copies/mL. The 3-year OS and PFS rates for patients with undetectable EBV-DNA after treatment was significantly higher than patients with detectable EBV-DNA (OS, 92.0% vs 69.8%, P = .031; PFS, 77.5% vs 50.7%, P = .028). Similar results were observed in stage I patients. EBV-DNA levels correlate with tumor load and a poorer prognosis in early-stage NKTCL. The circulating EBV-DNA level could serve both as a valuable biomarker of tumor load for the accurate classification of early-stage NKTCL and as a prognostic factor.

scholarly journals An ELISA method to compute endpoint titers to Epstein–Barr virus and cytomegalovirus: Application to population-based studies

2014 ◽  
Vol 408 ◽  
pp. 64-69 ◽  
Author(s):  
Raymond P. Stowe ◽  
R. Jeanne Ruiz ◽  
Christopher P. Fagundes ◽  
Robin H. Stowe ◽  
Min Chen ◽  
...  
Keyword(s):  
Epstein Barr Virus ◽  
Population Based ◽  
Elisa Method ◽  
Barr Virus ◽  
Epstein Barr

scholarly journals Characterization of the Epstein–Barr virus BALF2 promoter

1999 ◽  
Vol 80 (10) ◽  
pp. 2747-2750 ◽  
Author(s):  
Chien-Hui Hung ◽  
Shih-Tung Liu
Keyword(s):  
Transcription Factors ◽  
Epstein Barr Virus ◽  
Early Stage ◽  
Lytic Cycle ◽  
Mobility Shift ◽  
Response Elements ◽  
Barr Virus ◽  
Epstein Barr ◽  
Mobility Shift Assay

BALF2, which encodes the major DNA-binding protein of Epstein–Barr virus (EBV), is expressed during the early stage of the lytic cycle. The location of the BALF2 promoter was identified by primer extension, which indicated that the transcription start is located at nucleotide 164,782 of the EBV genome. Transfection analyses revealed that, similar to other EBV early promoters, the BALF2 promoter is activated by the EBV-encoded transcription factors Rta and Zta. The promoter is also synergistically activated if both transcription factors are present in B lymphocytes and in epithelial cells. Deletion analysis and electrophoretic mobility-shift assay revealed that the region between nucleotides −134 and −64 contains Zta- response elements and the region between nucleotides −287 and −254 contains Rta-response elements. This study demonstrates the importance of Rta and Zta in regulating the transcription of EBV early genes.

scholarly journals An EBV+ lymphoepithelioma-like cholangiocarcinoma in a young woman with chronic hepatitis B

2019 ◽  
Vol 12 (7) ◽  
pp. e229520 ◽  
Author(s):  
Sofia V Gearty ◽  
Ayman Al Jurdi ◽  
Meredith E Pittman ◽  
Renuka Gupta
Keyword(s):  
Chronic Hepatitis ◽  
Nasopharyngeal Carcinoma ◽  
Epstein Barr Virus ◽  
Systemic Chemotherapy ◽  
Early Stage ◽  
Treatment Options ◽  
Rare Type ◽  
Barr Virus ◽  
Epstein Barr ◽  
Almost All

Epstein-Barr virus (EBV) is implicated in the tumorigenesis of a variety of malignancies, including Burkitt’s lymphoma, Hodgkin’s disease and nasopharyngeal carcinoma (NPC). EBV+ lymphoepithelioma-like cholangiocarcinoma (LELCC) is a rare type of intrahepatic cholangiocarcinoma with a distinct pathology and poorly understood treatment options. Morphologically, this neoplasm resembles undifferentiated NPC, a commonly EBV+ tumour with a prominent lymphoid infiltrate. Almost all of the current literature regarding LELCC describes early stage tumours that are treated surgically and achieve good outcomes. In contrast, this report documents a late stage LELCC treated unsuccessfully with systemic chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document